FIG. 4.

Lower HSV-2-specific cellular response in animals infected after application of MZC compared to CG. (A) ICS staining of HSV-2-responsive CD4⁺ or CD8⁺ T cells in blood taken 23 weeks post-SHIV-RT/HSV-2 cochallenge from animals treated with MZC (n=6 HSV-2⁺ and n=2 HSV-2⁻) or CG (n=5 HSV-2⁺ and n=1 HSV-2⁻). Three animals were HSV-2⁻ in the MZC group, but a blood sample from one was unavailable at this time point. (B) Polyreactive CD4⁺ and CD8⁺ lymphocytes relative to single cytokine-reactive cells in blood from CG-treated HSV-2⁺ animals.